NEW YORK, Dec. 23 (GenomeWeb News) - An investment bank today downgraded its outlook for Thermo Electron despite the revenue growth expected by the company in 2006.
Needham & Co cut Thermo Electron's shares to "Buy" from "Strong Buy."
As reported in yesterday's GenomeWeb News, Thermo Electron expects total revenue for 2006 to grow 7 percent, to between $2.78 billion and $2.83 billion. According to Reuters Estimates, the company's guidance misses Wall Street's sales expectations of $2.89 billion.